Why is retatrutide more surface-active than other peptides?

Its fatty-acid chain makes it amphipathic, actively driving it to air-liquid interfaces where peptides denature. Foaming matters more here.

Can it be quantified at 280 nm?

Yes. At 39 residues on a GIP scaffold it contains aromatic residues, unlike several shorter peptides in this library.

Retatrutide Molecular Structure and Properties

The short answer

Retatrutide is a lipidated 39-residue peptide of approximately 4,731 Da, supplied as a white lyophilised powder. Its fatty-acid chain makes it amphipathic, which affects solubility behaviour in ways an unmodified peptide of the same length would not show.

Key facts

Physical form: White lyophilised powder
Residues: 39
Reported MW: ~4,731 Da
Lipid: C20 diacid at Lys17
Character: Amphipathic
Class: Lipidated peptide

What lipidation does to physical behaviour

Attaching a twenty-carbon diacid to a peptide creates a molecule with a hydrophilic peptide portion and a hydrophobic tail. Amphipathic molecules behave differently from either extreme: they orient at interfaces, they can self-associate above a threshold concentration, and their solubility is more sensitive to buffer composition than an unmodified peptide's.

Why that matters at interfaces

All peptides denature at air-liquid interfaces, which is why shaking is discouraged. A lipidated peptide is more surface-active than most, because the hydrophobic tail actively drives it to the interface. Foaming is therefore more consequential here than for a highly hydrophilic short peptide such as Selank or TB-500.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £49.99

Composition and analysis

At 39 residues on a GIP scaffold the peptide contains aromatic residues, so absorbance near 280 nm is available for quantification. Unlike several shorter peptides in this library that lack any aromatic residue. Mass spectrometry against the stated mass is the identity check, with the caveat that the expected value itself is reported rather than database-verified.

Why a 39-mer is a demanding synthesis

Coupling efficiency compounds across every cycle. At 99% per step, thirty-eight couplings finish around 68% full-length before purification; at 98% it falls to about 46%. Add the conjugation chemistry for the lipid and linker, and retatrutide is among the more difficult syntheses in the catalogue, which is directly relevant to what a purity figure means for it.

Comparison within the incretin family

Semaglutide at 4,114 Da carries a C18 diacid; tirzepatide at 4,813 Da carries a C20; retatrutide at approximately 4,731 Da also carries a C20. All three are lipidated peptides of similar size built for the same reason, and their handling characteristics are correspondingly similar, which is more useful to know than any single figure.

Frequently asked questions

Why is retatrutide more surface-active than other peptides?: Its fatty-acid chain makes it amphipathic, actively driving it to air-liquid interfaces where peptides denature. Foaming matters more here.
Can it be quantified at 280 nm?: Yes. At 39 residues on a GIP scaffold it contains aromatic residues, unlike several shorter peptides in this library.
Is 39 residues a hard synthesis?: Yes. At 99% coupling efficiency per step, thirty-eight couplings finish around 68% full-length before purification.

Extended research context

The Retatrutide Research deep dive

Deep dive: how the triple-agonist scaffold was engineered

Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance. This is the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.

The TRIUMPH Phase 3 programme in context

TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator (FDA, EMA, or MHRA) has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.

How retatrutide differs from tirzepatide and semaglutide at the mechanism level

Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press, but the pharmacology is more nuanced than the label implies.

Research applications

▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
▸Reference material for teaching incretin pharmacology in university-level courses

Handling checklist

✓Store lyophilised vials at −20 °C; protect from light and humidity
✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
✓Once reconstituted, store at 2–8 °C and use within 28 days
✓Verify batch CoA: HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
✓Do not administer to humans or animals. Research use only

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing retatrutide with tirzepatide in supplier catalogues

Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.

✗ Using tap or filtered water for reconstitution

Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water, never lab DI water.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum